Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.
+ 2 more risks
Excellent balance sheet and fair value.
Share Price & News
How has Adaptimmune Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 473A's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 473A underperformed the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: 473A underperformed the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Adaptimmune Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Adaptimmune Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 473A (€3.36) is trading below our estimate of fair value (€7.86)
Significantly Below Fair Value: 473A is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 473A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 473A is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 473A's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 473A is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).
How is Adaptimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 473A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 473A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 473A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 473A's revenue (58.6% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 473A's revenue (58.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 473A's Return on Equity is forecast to be high in 3 years time
How has Adaptimmune Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 473A is currently unprofitable.
Growing Profit Margin: 473A is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 473A is unprofitable, and losses have increased over the past 5 years at a rate of -30.8% per year.
Accelerating Growth: Unable to compare 473A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 473A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 473A has a negative Return on Equity (-97.49%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Adaptimmune Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: 473A's short term assets ($147.0M) exceed its short term liabilities ($37.4M).
Long Term Liabilities: 473A's short term assets ($147.0M) exceed its long term liabilities ($23.2M).
Debt to Equity History and Analysis
Debt Level: 473A is debt free.
Reducing Debt: 473A had no debt 5 years ago.
Inventory Level: 473A has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 473A's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 473A has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 473A has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -38.3% each year.
What is Adaptimmune Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 473A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 473A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 473A's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 473A's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 473A's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ad Rawcliffe (47yo)
Mr. Adrian Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune The ...
CEO Compensation Analysis
Compensation vs Market: Ad's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD805.15K).
Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.
|CEO, Principal Accounting Officer & Director||0.4yrs||US$1.41m||0.0024% $10.9k|
|Co-Founder & Chief Business Officer||0yrs||US$1.28m||0.23% $1.0m|
|Chief Operating Officer||2.9yrs||US$1.29m||0.0028% $12.4k|
|President of Research & Development||4.9yrs||US$2.60m||0.029% $132.0k|
|Interim CFO||0.3yrs||no data||no data|
|Vice President of Communications & Investor Relations||0yrs||no data||no data|
|Senior Vice President of Clinical Development||4.8yrs||no data||no data|
|Head of Biometrics and Vice President||4.4yrs||no data||no data|
|Head of Autoimmune Group||4.1yrs||no data||no data|
|Head of Process Development||4.1yrs||no data||no data|
Experienced Management: 473A's management team is considered experienced (4.1 years average tenure).
|CEO, Principal Accounting Officer & Director||0.4yrs||US$1.41m||0.0024% $10.9k|
|Chairman of the Board of Directors||3.1yrs||US$225.49k||0.51% $2.3m|
|Non-Executive Director||0yrs||US$2.64m||1.51% $6.8m|
|Non-Executive Director||3.3yrs||US$199.78k||no data|
|Non-Executive Director||5yrs||US$186.34k||0.047% $211.4k|
|Non-Executive Director||3.7yrs||US$190.46k||no data|
|Non-Executive Director||5yrs||US$186.34k||no data|
|Non-Executive Director||4.9yrs||US$179.26k||0.015% $67.9k|
|Non-Executive Director||3.3yrs||US$193.01k||no data|
|Independent Non-Executive Director||1.6yrs||US$309.79k||no data|
Experienced Board: 473A's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 473A insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.
Adaptimmune Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Adaptimmune Therapeutics plc
- Ticker: 473A
- Exchange: DB
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$487.778m
- Listing Market Cap: US$449.390m
- Shares outstanding: 130.07m
- Website: https://www.adaptimmune.com
Number of Employees
- Adaptimmune Therapeutics plc
- 60 Jubilee Avenue
- Milton Park
- OX14 4RX
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ADAP||NasdaqGS (Nasdaq Global Select)||Yes||ADS EACH REPR ORD SHS (SPONS)||US||USD||May 2015|
|473A||DB (Deutsche Boerse AG)||Yes||ADS EACH REPR ORD SHS (SPONS)||DE||EUR||May 2015|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune’s PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 23:24|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.